SCHEMBL979325

SCHEMBL979325

CC(C)(C)OC(=O)NC(C)(C(=O)OC(C)(C)C)c1cc(F)cc(F)c1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 3/20 0.36
DGAT1 O75907 1/20 0.34
SLC6A3 Q01959 1/20 0.33
KDM4E B2RXH2 1/20 0.33
APLNR P35414 1/20 0.33
CYP17A1 P05093 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
CTSS P25774 2/20 0.32
CTSK P43235 2/20 0.32
RXFP1 Q9HBX9 1/20 0.32
KCNQ4 P56696 1/20 0.31
KCNQ5 Q9NR82 1/20 0.31
TRPA1 O75762 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL980274 0.88 CTSS (0.39) AAK1SLC6A3KDM4ECTSSCTSK
SCHEMBL17040319 0.82 APLNR (0.38) AAK1SLC6A3KDM4EAPLNRALDH1A1
SCHEMBL6343801 0.78 AAK1 (0.36) AAK1SLC6A3KDM4EAPLNRALDH1A1
SCHEMBL13099832 0.78 KCNN4 (0.44) GAANFKB1NFKB2RELACTSS
SCHEMBL12077684 0.76 DGAT1 (0.36) DGAT1SLC6A3
SCHEMBL2947195 0.73 CTSS (0.43) CYP17A1GAACTSSCTSK
SCHEMBL2947196 0.73 CTSS (0.43) CYP17A1GAACTSSCTSK
SCHEMBL28860305 0.71 CA12 (0.43) CYP17A1RXFP1KCNQ4KCNQ5
SCHEMBL5969759 0.71 HDAC3 (0.46) AAK1ALDH1A1GAACTSSCTSK
SCHEMBL10885417 0.71 KCNN4 (0.46) AAK1KDM4EALDH1A1CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029575-B1 SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2014-10-22 EP disclosed
US-8765759-B2 Monocyclic CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2014-07-01 US disclosed
EP-2271346-B1 MONOCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2014-01-01 EP disclosed
EP-2458991-A1 RADIOLABELED CGRP ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2012-06-06 EP disclosed
US-20120121508-A1 RADIOLABELED CGRP ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2012-05-17 US disclosed
US-20120121508-A1 RADIOLABELED CGRP ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2012-05-17 US disclosed
US-7893079-B2 Substituted monocyclic CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-02-22 US disclosed
WO-2011014383-A1 RADIOLABELED CGRP ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-02-03 WO disclosed
WO-2011014383-A1 RADIOLABELED CGRP ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-02-03 WO disclosed
US-20110021516-A1 MONOCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP (US) 2011-01-27 US disclosed
EP-2271346-A2 MONOCYCLIC CGRP RECEPTOR ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2011-01-12 EP disclosed
US-20100056498-A1 SUBSTITUTED MONOCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-03-04 US disclosed
US-7629338-B2 Substituted monocyclic CGRP receptor antagonists MERCK & CO., INC. (US) 2009-12-08 US disclosed
US-7625901-B2 Substituted monocyclic CGRP receptor antagonists MERCK & CO., INC. (US) 2009-12-01 US disclosed
WO-2009120652-A2 MONOCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2009-10-01 WO disclosed
US-20080318927-A1 Substituted monocyclic CGRP receptor antagonists MERCK SHARP & DOHME LLC 2008-12-25 US disclosed
US-20070265225-A1 Substituted monocyclic CGRP receptor antagonists MERCK SHARP & DOHME LLC 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021516-A1 MONOCYCLIC CGRP RECEPTOR ANTAGONISTS CCKAR, CALCRL, CCKBR AAK1 2740/4885DGAT1 4067/4885SLC6A3 1040/4885
US-20100056498-A1 SUBSTITUTED MONOCYCLIC CGRP RECEPTOR ANTAGONISTS QRFPR, CALCRL, EDNRB AAK1 2996/4885DGAT1 4421/4885SLC6A3 871/4885
US-20120121508-A1 RADIOLABELED CGRP ANTAGONISTS CALCRL, CALCR, GRPR AAK1 3577/4885DGAT1 1929/4885SLC6A3 330/4885
US-20080318927-A1 Substituted monocyclic CGRP receptor antagonists EDNRB, CALCRL, QRFPR AAK1 2807/4885DGAT1 4385/4885SLC6A3 1030/4885
US-20070265225-A1 Substituted monocyclic CGRP receptor antagonists QRFPR, CALCRL, EDNRB AAK1 2996/4885DGAT1 4421/4885SLC6A3 871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.